TacticScaleWhat PTC Therapeutics Does & How It Makes Money (PTCT)
Updated October 2026 · reflects PTC Therapeutics's latest reported financials
Biotech company developing and selling medicines for rare diseases. It earns revenue mainly by selling its rare-disease drugs in the U.S.
How PTC Therapeutics makes money
It earns revenue mainly by selling its rare-disease drugs in the U.S. and internationally through third-party distributors. It also has collaboration and licensing deals with partners such as Roche (Evrysdi) and Novartis (PTC518).
What PTC Therapeutics does
PTC Therapeutics is a New Jersey-based biopharmaceutical company, founded in 1998, that focuses on medicines for rare disorders. Its commercial portfolio includes Translarna and Emflaza for Duchenne muscular dystrophy, Evrysdi for spinal muscular atrophy (developed with Roche and the SMA Foundation), the gene therapy Upstaza (sold as Kebilidi in the U.S.) for AADC deficiency, and Tegsedi and Waylivra for other rare diseases. Products reach patients in the U.S. and abroad through third-party distributors. The pipeline includes sepiapterin for phenylketonuria, PTC518 from its splicing platform for Huntington's disease (licensed to Novartis under a collaboration agreement), and vatiquinone for Friedreich's ataxia from its inflammation and ferroptosis platforms. Partnerships with Roche, Novartis, Akcea Therapeutics and others add to its own drug discovery work.
Products & services
- Translarna
- Emflaza
- Evrysdi
- Upstaza (Kebilidi in the U.S.)
- Tegsedi
- Waylivra
What is PTC Therapeutics worth?
On an owner-earnings DCF, PTC Therapeutics's most-likely value is about $40 versus a recent price near $65 (38% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$14) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 6.3× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Sarepta Therapeutics (SRPT) · United Therapeutics (UTHR) · Protagonist Therapeutics (PTGX) · PTC (PTC) · BioMarin Pharmaceutical (BMRN)